# reload+after+2024-01-20 23:47:37.444376
address1§6 Tide Street
city§Boston
state§MA
zip§02210
country§United States
phone§857 520 9158
website§https://www.entradatx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§150
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Dipal  Doshi', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 902075, 'exercisedValue': 0, 'unexercisedValue': 7977112}, {'maxAge': 1, 'name': 'Mr. Nathan J. Dowden', 'age': 52, 'title': 'Chief Operating Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 654600, 'exercisedValue': 0, 'unexercisedValue': 1949125}, {'maxAge': 1, 'name': 'Dr. Natarajan  Sethuraman Ph.D.', 'age': 61, 'title': 'Chief Scientific Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 654600, 'exercisedValue': 0, 'unexercisedValue': 1413008}, {'maxAge': 1, 'name': 'Mr. Kory James Wentworth CPA', 'age': 43, 'title': 'CFO & Treasurer', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jared  Cohen J.D., Ph.D.', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kerry  Robert M.S.', 'title': 'Senior Vice President of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nerissa C. Kreher M.B.A., M.D., M.S.', 'age': 50, 'title': 'Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karla  MacDonald', 'title': 'Chief Corporate Affairs Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§4
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.463
priceToSalesTrailing12Months§5.837934
currency§USD
dateShortInterest§1702598400
forwardEps§-3.03
exchange§NGM
quoteType§EQUITY
shortName§Entrada Therapeutics, Inc.
longName§Entrada Therapeutics, Inc.
firstTradeDateEpochUtc§1635514200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§79717894-c8cd-3979-9495-cc41bc979565
gmtOffSetMilliseconds§-18000000
targetHighPrice§22.0
targetLowPrice§20.0
targetMeanPrice§21.0
targetMedianPrice§21.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§2.175
grossMargins§0.76288
ebitdaMargins§-0.35582
trailingPegRatio§None
